Latest / No Brain Behind / The New Era of Duchenne Muscular Dystrophy
Transcript
- 0:00On behalf of the Society for Equity Neuroscience, welcome to No Brain Behind.
- 0:04The mission of the Society for Equity Neuroscience or Sequence is to enhance brain health
- 0:13equity through scientific research. This podcast is dedicated to conversations with equity-focused
- 0:19neuroscientists and thought leaders. Our guests are working to understand and address barriers
- 0:25to and facilitate us up optimal brain health and nervous system function for everyone,
- 0:31everywhere. No brain behind explores cutting-edge research methods, amplifies new discoveries,
- 0:37ambassadors, collaboration within the scientific community. I'm Dr. Githangeli Das.
- 0:43I am Dr. Annalkadeh Nathihada and I'm Dr. Chris Orlando. We are a clinician scientist in the
- 0:49field of health equity neuroscience who have the distinct pleasure of being your host on No Brain
- 0:55Behind. Join us as explore the scientific challenges and innovations shaping the future of equity
- 1:03neuroscience. Hello and welcome to another episode of No Brain Behind. I am your host, Githangeli Das.
- 1:13And today I'm so excited to introduce our guest, Dr. Natalie A. Kukulka, a child neurologist at
- 1:20primary children's hospital in Utah. Dr. Kukulka specializes in neuro-muscular disorders,
- 1:26and today we will be discussing the Duchenne muscular dystrophy. A disease where over time we've been
- 1:33able to see significant progress in treatment advances that has been really great for our patients
- 1:38and for their families. But with progress, new questions are always arising, including ways to
- 1:45have equitable access to these advancements as well as some ethical considerations as we progress
- 1:52in time with patients who have access to advancements. Thank you again, Dr. Kukulka for joining us today.
- 1:59Thank you so much for having me. I'm really excited to have this conversation and get people excited
- 2:03and talk more about these transitions. Awesome. So to start with, for our listeners who are not super
- 2:09familiar with it, can you tell us more about what Duchenne muscular dystrophy is, who it affects,
- 2:15and what this disease trajectory typically looks like, especially for those of us in the adult
- 2:21neurology world. We'd also have to know more about this transition into adolescents and adulthood
- 2:26for these patients. Sure, of course. So Duchenne muscular dystrophy, or abbreviated as DMD, is one of the
- 2:33most common forms of muscular dystrophy. And for the available literature, the estimated incidence is
- 2:39about 1 and 3 and a half to 6,000 of live-born males in the United States, and about 7 cases for 100,000
- 2:46of males born globally. It is an ex-linked recessive neuromuscular disorder caused by mutation in the
- 2:52DMD gene, which encodes dystrophy. So because it is an ex-linked recessive disorder, it affects
- 2:58primarily males, but females can also be carriers and exhibit a broad spectrum of clinical
- 3:03manifestations. So they can be asymptomatic, but 10 to 20% can be manifesting carriers and present
- 3:10with muscle weakness and cardiomyopathy. So the big question is, what is this dystrophy,
- 3:15or what is this DMG doing? And it is a critical subcircle mammal protein that provides structural
- 3:21stability to the muscle fibers. So the way that I explained it to our families and patients is
- 3:25that it is essentially like a molecular shock absorber for muscle fibers. And it connects the
- 3:30internal side of skeleton to the external membrane, and it helps maintain structural integrity
- 3:35during contraction. So this is a disorder that will over time result in progressive muscle
- 3:40degeneration. And so historically, like really truly often till the early 2010s, patients with
- 3:48Duchenne Muscular Dystrophy would present to a pediatrician or our office between the ages of like three
- 3:52and six years of age with progressive proximal muscle weakness followed by loss of
- 3:58emulation, respiratory failure, and then cardiomyopathy ultimately leading to premature death
- 4:03often by the third decade of life. And I'm really excited to be here to talk about if that story is
- 4:08now changing. So we have advances in cardiovascular respiratory care, cardiovascular management,
- 4:13multidisciplinary care, and disease modifying therapies that are truly significantly having an
- 4:18impact and extending both survival and quality of life. So as a result, we're now preparing
- 4:24ourselves and uncovering this process, we're going to be caring for an entirely new generation of
- 4:28young adults with the Shen Musco dystrophy. And they will transition into our adult neurology
- 4:33colleagues offices. But of course, they will bring, I think, new opportunities and challenges
- 4:38surrounding the transition, education, employment, independence, and kind of long term, I think,
- 4:43adult care that's important to highlight. Great. That was a really great overview. And you've kind
- 4:51of touched on this a little bit about that ever changing treatment landscape. But can you kind of
- 4:56give us a little bit more of a sense of what the latest advancements in therapy are or have been
- 5:01for DMD? Absolutely. And I will try to keep it as succinct as possible and kind of paint a
- 5:06picture. I feel something like that can be a podcast in itself, but the field has obviously undergone
- 5:13a remarkable transformation and it has truly impacted the conversations that we can now have with
- 5:18our families. So the earliest therapeutic milestone in the Shen Musco dystrophy occurred in
- 5:23like the 1980s with the introduction of corticosteroids, particularly prednisone or prednisolonin's
- 5:28liquid form. It demonstrated meaningful clinical benefits, including improved emulation,
- 5:34increased muscle strength, and preservation of pulmonary function. So for a decade, this was the
- 5:38backbone of the Shen Musco dystrophy management. But long term corticosteroids, as we all know, come
- 5:43with their own side effects, right? Including weight gain, growth suppression, osteoporosis,
- 5:48hypertension, cataracts, behavioral changes in somnial, increased susceptibility infections,
- 5:52just to kind of list a few. And because of those long term complications, there's been a lot of
- 5:56research efforts to develop alternative corticosteroids and improve the safety profile. So this
- 6:02leads us kind of to 2017 when the FDA approved the medication called the flaza cord, which is a
- 6:08steroid with a slightly different form of kinetic properties. And it has been associated with lower
- 6:13rates of waking compared with prednisone, but also higher frequencies of growth delay,
- 6:18cushionite appearances, and cataracts. So still not sort of a perfect or a great alternative.
- 6:23In 2024, the war alone came on the scene representing the next generation of associates
- 6:29steroid that targets dual nuclear receptors, essentially to reduce inflammation and cardiomyopathy,
- 6:35while attempting to avoid many of the mineral chlorochoid receptor related side effects seen with
- 6:41the traditional glucocorticoid. So again, another alternative that we now have served in our arsenal.
- 6:46And then in 2024, also, we have the first non-surreal therapy entered, the treatment lens
- 6:53give called jibinist acts, which is a histone deacetylase inhibitors. It works unlike our other medications.
- 6:59It works by modulating gene expression to reduce inflammation, increase fibrosis, and promote
- 7:04muscle regeneration. So the side effects are also a little bit different. So we have a dose related
- 7:09thermosytopenia, myelus depression, and QT interval prolongation so that overall requires sort
- 7:15of regular laboratory monitoring. And we have found that frequently the use of this medication
- 7:21can be a disqualifying factor from clinical trials. So it's important to recognize the glucocorticoids
- 7:26and anti-inflammatory therapies primarily mitigate disease burden and preserve function,
- 7:31but they do not correct the underlying genetic cause of duchin muscular dystrophy.
- 7:36And so a major shift towards disease modifying therapy occurred with the development of molecular
- 7:42approaches aimed at kind of restoring that dystrophin expression, including exonskipping agents
- 7:47and gene replacement therapies, which introduced a new era of mutation specific personalized treatment
- 7:52strategies based on the patient's genotype. So we have now exonskipping therapies that work by
- 7:57restoring the dystrophin breeding frame. And these treatments are currently limited to patients with
- 8:02mutations imaginable to exon 45, 51, and 53 skipping, although there's additional ones in the works.
- 8:10And so meaning that only certain types of patients are eligible for these therapies. And then as
- 8:15we all know, kind of a landmark advancement occurred in 2023 would be approval of the
- 8:20dystroph gene, maxapyra-vec, trying to think that fast ten times. If the first gene replacement
- 8:26therapy for duchin and that delivers the truncated micro-dustrophin gene using a non-pathogenic
- 8:32AABRH 74 viral vector that significantly target skeletal and cartet muscle tissue. But with the
- 8:39clinical availability of this therapy, that clinical availability has been fluid with recent regulatory
- 8:44fluctuations, including the emperor of D.U. withdrawal and reinstatement, illustrating that even with
- 8:50the treatment being available, accessibility landscape, bridging therapy can continue sort of
- 8:54to evolve moving into the future. And so that's sort of what we have, I think, available right now
- 8:59in our arsenal. There are other really exciting things on the horizon, beginning with molecular
- 9:04treatments. I think are opening them molecular treatment era, including PPMOs, advanced delivery
- 9:09system like DG9 peptide, some people are also working on crisper approaches. So I think there's
- 9:14many, many more therapies to come. And just briefly, I think in parallel with the therapy
- 9:19advancements, we also have comprehensive supportive care that remains essential, but that also
- 9:24has made huge milestones in improvements as far as respiratory management, cardiac monitoring,
- 9:29physical therapy, orthopedic interventions, and they've all played a critical role in managing
- 9:33complications, improving quality of life. And I think overall extending survivorship for
- 9:38individuals living with Dushan muscular dystrophy. So I think the last thing that I'd want to just
- 9:42mention is it's important to remember that none of the therapies, the medications are curative
- 9:47at this point. So they slow progression and they preserve function, the patients still require
- 9:52comprehensive multidisciplinary care, involving many, many specialists. And so the exciting part is that
- 9:57we are no longer simply managing complications. And now we're beginning to manage sort of the natural
- 10:03history of disease and seeing how that evolves. I truly appreciate the clarification that like we're
- 10:09doing our best to actually manage the disease now, but it's not really curative. So I think it's a
- 10:14really helpful thing to learn and understand about kind of what these changes in therapy mean
- 10:19long term for our patient. I do want to talk a little bit more about what these access to this
- 10:24treatments will look like moving forward. Because one of the early challenges from my understanding
- 10:30with the first gene therapy that was approved for DMD was that it has an incredibly high price point
- 10:37for even a single dose. How do you think about a treatment that is both an incredible breakthrough
- 10:43and is potentially also out of reach for many families? And how do you approach that conversation
- 10:50with your patients and their families when they come to see you in clinic? Yes, I think this is
- 10:55probably one of the biggest ethical questions with the Shenmue Scherid Distribute Treatment today.
- 11:01I think as physicians we're incredibly excited that we finally have every second
- 11:06meaningfully alter disease progression, but that excitement has to be balanced with honesty. And so I
- 11:11think the treatments are incredibly expensive. Eligibility can certainly be limited, not only
- 11:16within the United States, but also globally. Access often depends on insurance approval. Treatment
- 11:21center availability, geographic location, and so it's not simply just the medical need. And when I
- 11:26speak with families, I try to focus on transparency, right? So we discuss what we know, we discuss what we
- 11:31don't know, any potential benefits, any potential risks, there have been deaths associated with gene
- 11:36therapies. And so I can review that and discuss that, talk about the uncertainties of how much that
- 11:42will affect their children and the kind of the practical realities of it. So Scherid decision-making
- 11:47is essential because there isn't really a universally right answer, I think, for every family. And then
- 11:52in a system level, we also have an ethical responsibility to ensure that scientific innovation
- 11:57doesn't widen health care disparities, right? So the breakthrough only fulfills its promise
- 12:01if patients can actually receive it. And what I've seen and what I remember many, many years ago
- 12:06as a medical student rotating in a hospital, and I don't want to drop any names here, but it was a
- 12:11big institution that was receiving applications for different patients globally trying to attain
- 12:16gene therapy. And it was kind of a lottery or a system like, who do we accept, who do we not accept?
- 12:21And with my Polish background, I know that currently gene therapy is not even available or proposed
- 12:25to patients and in Poland. And so then there's very brilliant treatments even within the United States.
- 12:30And so I think we have a lot of work coming up ahead of us.
- 12:33That was an incredibly powerful statement, that scientific innovation, it doesn't really do
- 12:40much, it doesn't really matter if it widens health care disparities. I think it's such a powerful
- 12:46statement. I truly appreciate it because it truly is kind of the crux of this conversation we're
- 12:51having here today. Something else that I wanted to touch on to you is you had mentioned that,
- 12:56you know, like with this, there is still this responsibility to have ongoing, like,
- 13:01multidisciplinary care for our patients. A real challenge for a lot of families is the actual
- 13:07access to a specialized provider who can manage the MD. Like, not only are child neurologists not
- 13:14very prevalent nationally, but somebody that specializes in neuromuscular child neurology is even
- 13:20less accessible. Something that we recognize here in the state of Utah where we're getting patients
- 13:26from like all over the mountain west to come see us, the access to care is truly a bit challenge.
- 13:33How does that factor into consideration for their patients who are maybe traveling a large distance
- 13:42to see you or to see other specialists or who, you know, we are relying a lot on their parents or
- 13:48family members being able to transport them back and forth as well as the overall burden of just
- 13:54like taking care of the kid who is dealing with a lot just in terms of their mobility. How is that
- 13:59factoring into your conversations with patients? So this can become definitely a treatment barrier
- 14:05in itself. And I think, as you've mentioned, many advancement therapies are only available at
- 14:10specialized neuromuscular centers and there's maps of those specialized neuromuscular centers
- 14:15and they're quite bars, especially on the west coast. And so families do have to travel several hours.
- 14:20I mean, I have patients from everywhere around Utah, Wyoming, Montana, we have people from Arizona
- 14:26even coming out here, people from Nevada and that just the number and that population keeps growing
- 14:31and those are the people that actually can come to us and can reach us so that access spreads across
- 14:36different state lines and the travel isn't just inconvenient, but it also means missed work,
- 14:41missed school, transportation costs, hotel stays, I think care and care are burdened. And so here,
- 14:47shout out to our social workers, they can help us make these things possible. So we work really
- 14:51closely with social workers, especially one in our interdisciplinary clinic that helps us to
- 14:56accommodate the long travels for families staying at Ronald McDonald's house. How would this look
- 15:00like if the patient were to receive gene therapy and this have to remain here for multiple appointments,
- 15:06subsequent lab draws and things like that because also subsequent lab draws among other patient
- 15:11laboratories have proved to be tremendously difficult and unremuliable, especially in kids where we
- 15:16think that there might be impaired liver function or other complications. So we also have to remember
- 15:21that Dusha Mosqueer Distribute Management is not done just in one annual visit, right? So if these
- 15:26children require ongoing cardiac monitoring, pulmonary evaluations, physical therapy, lab draws,
- 15:31lab monitoring, multidisciplinary coordination. And so it certainly is very challenging for patients
- 15:37and for families and I'm incredibly indebted to them for them to be able to bring their kids over
- 15:42to us for us to be able to assess them and help them in the best way that we can. I think as a brand new
- 15:47faculty, I usually reach out to our division heads and I'm like, "But me and coach, could be in
- 15:52somewhere in a different state or let me travel somewhere else." And so we are trying to at least
- 15:56do outreach neuromuscular clinics to Southern parts of Utah, which should help with an accessibility
- 16:02aspect. They think we're trying to also branch out to other states. I think with the innovation
- 16:06of telemedicine that can tremendously impact patient care. So I am very fortunate and privileged to be
- 16:12licensed in multiple states and so I can do video visits. But the nature of the neuromuscular care
- 16:17and evaluation is that you must put your hands on the patient in the most appropriate way, right?
- 16:21But you want to look at increased tone, increased muscle strength, look at how they're functioning,
- 16:26assess for a pulmonary, cardiac function, all these things that unfortunately still cannot do,
- 16:31via telemedicine, but to the extent that we can address questions or concerns or urgent needs,
- 16:37I think telemedicine has become a tremendous tool to be able to reach those families.
- 16:41I think ideally, they should be building models that combine specialized expertise with local care,
- 16:47which means partnering with primary care physicians and local specialists so families can receive
- 16:52expert care without having to shoulder every aspect and that burn themselves. But I think that
- 16:57we still have a long way that was to serve relationship with all of the local providers.
- 17:01Yeah, totally. There is so much benefit in just that partnership aspect of extensive care
- 17:08model that we're building. And again, I agree with you. I think that we have this really great
- 17:15advancements and kind of even the the technology being able to see our patients on the video,
- 17:20but there's still that need to actually physically see them and check in with them in person.
- 17:25I do want to shift gears a little bit and talk about what the advancements in management of
- 17:31DMD means in terms of extending life and what that means in terms of optimizing quality of life.
- 17:38I do think that there is sometimes a tension in rare disease medicine between actually extending
- 17:43life and optimizing the quality of that life. And how do you navigate that conversation with DMD
- 17:51patients and families moving forward? Yeah, I think that is a great question. I don't know that I
- 17:56have a part of the answer or navigatory tools for that, but I think now the goal is in simply
- 18:02to add years to life. It's to add like to those years, right? So I think as survival improves,
- 18:08our conversations have naturally shifted and well-shift from asking, how do we prolong life to a kind of
- 18:13life? Are we hoping to build for this young person and that should and hopefully we'll focus on
- 18:19things like education and friendships and employment and relationships and dependence, mental
- 18:24health, pursuing meaningful personal goals. And I think every family defines success very differently.
- 18:30So these discussions have to be individualized and revisited over time as these priorities evolve.
- 18:37And to put kind of like advertisement or a pearl of entertainment, there's a wonderful and beautiful
- 18:43movie made. It's called the remarkable life of Evelyn. So it's a secret life, a young
- 18:47patient with Dusha Muscat, a district that lived within the world of warcraft games. And I'm not
- 18:53a game in myself, but that completely gave me a different sort of outlook on how these patients
- 18:57can also fulfill themselves. And so this reality came through the family or to the parents after the
- 19:03patient already passed away. But within this game, he had friends and relationships and found love
- 19:08and was able to give really mature counseling to other people that were part of the game. So I think
- 19:13the questions again will be, how do we get bringing them to our patients as we think about extending
- 19:20life and as we work towards extending the years of life, but also how do we give quality of life
- 19:25to the things that they're really excited about. Another thing that we wanted to talk about too is
- 19:30that the typical primary endpoints and clinical trials don't really include things like you just
- 19:37mentioned, like social participation, access to education, independent. How do you incorporate those
- 19:44other things and how you're evaluating whether a treatment is truly working versus it's really not
- 19:52providing that benefit in the way that we were hoping that it would.
- 19:56Yes, I mean, I think we need to broaden our definition of success in that therapy preserves a few
- 20:01or meters on a walking test, but the child is isolated, depressed, you know, unable to participate in
- 20:06school, legs, independence. We've only sort of measured part of the story. So things like patient
- 20:12reported outcomes, mental health assessment, educational participation, again, the aspect of them,
- 20:18in measures of autonomy, should increasingly become part of both research and routine clinical care.
- 20:23Now it's really difficult to advocate for that because it's not maybe as exciting to report on those
- 20:29things or we don't have enough funding to really create some of those that even design them in the way
- 20:33that could address some of those questions, but I think as caregivers we should at least
- 20:36grow up upon those questions and kind of help from our perspective to see how we can open up those
- 20:40areas and focus on supporting our patients. I think those are outcomes that families talk about in
- 20:46every day of life and clinic, and ultimately they determine whether someone is living well and not
- 20:51simply living longer. And so I think, um, and certainly these answers should shape our medical decision
- 20:55just as much as pulmonary function tests and cardiac imaging, but, you know, as doctors I think
- 21:00we always are like, okay, let's focus on the medical aspects of things and hopefully we don't forget
- 21:04about the other things that make a person whole. I think instead of defining quality of life
- 21:09for patients, we should ask webinars to them. And for one person, it might be attending college for
- 21:13another one, it might be maintaining employment or having some form of employment, gaming with
- 21:18friends, dating, traveling, being remaining involved in family life. So I hope that that remains sort
- 21:22about the objective of care in addition to the medical care that we're really focused on providing
- 21:27to patients. Again, I think iftegears and talk about the long term when it comes to managing our
- 21:35patients with DMD, as an adult neurologist, I think one of the things I kind of am looking at in
- 21:42the future is when these patients are transitioning into seeing and potentially needing an adult neurologist,
- 21:50which I think is again, a very exciting time to think about, but as somebody who in our training,
- 21:56we only do three months of child neurology, I think it's an important thing for us to consider what
- 22:00that looks like for us in terms of taking care of our patients. What does a well-designed transition
- 22:06of care look like for a DMD patient? And in your experience, have you seen that happen and how often
- 22:13have you actually been seeing that happen? So first of all, welcome to child neurology. Please
- 22:19comment a little bit longer than three months. I think what is a Game of Thrones winter is coming. And
- 22:24it's like DMD is coming. It is coming to you guys. It is coming to our adult neurology providers.
- 22:30And I think so much discrepancy and variability and how that's performed even across the country,
- 22:35right? So ideally, it doesn't just like strictly happen in age 18 or 19 or 22 or whatever the
- 22:40cutouts are that the hospitals have. Ideally, it starts years earlier by gradually helping adolescents
- 22:46understand their condition, participating in medical decision, learning to advocate for themselves
- 22:51and prepare for adult health care system. As I working here at the University of Utah and primary
- 22:56children, I've just been taken aback and impressed by the involvement of different parties in our
- 23:01transition clinics or in our attempts to transition clinics, right? So we have a provider that
- 23:06literally is the transition guide and talk to families early on about what the transition might look
- 23:10like. And I think a successful transition in mind, my includes details communication between
- 23:16pediatric and adult providers, attention to education and vocational playing that we're really
- 23:20truly missing mental health support, which we do definitely have in pediatric clinics, not sure
- 23:25how much we have in adult clinics and sort of continued multidisciplinary care. I think we
- 23:31are blessed with having Dr. Butterfield who is one of a kind and just in the pediatric multidisciplinary
- 23:37clinic and is in the adult multidisciplinary clinic and so he is our bridge. I've been fortunate
- 23:42enough to spend a couple of different aftermins in that adult clinic and see what the transition
- 23:46looks like and when it's him, it's flawless, right? But when we can't clone him, unfortunately,
- 23:51and we can't put him in every single clinic. And so I think, you know, across the country that
- 23:55transition still remains fragmented. So I think adult providers are not experienced with D&D and
- 24:00they might be afraid of it or maybe never thought that they have to know as much about it because of
- 24:04the expiration of these patients within the third decade of life. I think institutional practice is
- 24:08very considerably. I think many young adults experience disruption and continuity of care during
- 24:14this very vulnerable period of time and we should really hone in on that and try to improve that.
- 24:19There's also one aspect that we didn't talk about as much earlier, but also the mental
- 24:24burden or the psychosocial challenges in D&D, right? So newer development is also impacted because
- 24:30we know that the absence of district and ice forms profoundly impacts the brain and so these children
- 24:35they're now expected to be adults and expected to set up their own appointments and expected to fall
- 24:40up on things. In fact, their children maybe in a slightly older body and so I think we need to do a
- 24:46better job and how we do that is a million dollar question, but I'm open to any suggestions or
- 24:50collaboration from our adult colleagues. Yeah, I agree with you. I think that we do need to connect
- 24:56and kind of support that transition of care and as you're Dr. Butterfield has been so instrumental
- 25:02in making that transition of care better, but I think that's we only have one of him here and we're
- 25:08lucky to have him here in Utah. We need it elsewhere. What are some structural or systemic changes that
- 25:16you would like to see that would make these transitions of care more equitable and more effective?
- 25:20I'd like to see transition viewed more as a formal clinical process rather than like okay well
- 25:26they're going to undergo this transfer in like good luck. So more of a formal clinical process
- 25:31rather than a transfer of medical records. So this means dedicated position clinics,
- 25:37standardized transition summaries, stronger collaboration between pediatric and adult neuromuscular
- 25:42teams. I think we need a greater integration of primary care into the process, kind of expanded
- 25:48access to social workers, please, please, please, psychologists, psychiatrists, vocational
- 25:53counselors and disability services because I think that's where we're really lacking in bed as
- 25:56the component that could truly impact and provide that meaning to the expanded life for these patients.
- 26:02I think the health care system also to recognize that adulthood with Dushan Muscare Distribute is now
- 26:07expected and is not going to be an exceptional phenomenon and we need to build infrastructure
- 26:14accordingly to that. So again, open-to-the-suggestions, collaborations and future processes where we can
- 26:19improve the transition. I do envision a future where our adult neurology education is going to have
- 26:28to expand more and we are going to have to spend more time in the clinical or like the outpatient
- 26:32signing and learn more about our patient. I envision a future where it's going to have to just to help
- 26:38better take care of these patients as well. Yeah, and I think we, you know, as neuromuscular
- 26:43subspecialists, we do get a little bit more of a training right. So even when you're past neurology,
- 26:47when you enter the neuromuscular space, you do get exposure to adult pediatric patients in the
- 26:51variability, but geographically also that the amount of patients, very variable east coast, west coast,
- 26:58you know, midwest, and then people always have kind of a preference of like, well, I'm only adult,
- 27:02so I'm going to see one patient of pediatric and that's good enough, but I think that is also
- 27:06be changing a little bit more. I wanted to talk a little bit more like we've kind of touched on
- 27:12this as well about actual support of patients and communities and caregivers, community organizations
- 27:19like the Muscular Distribute Association plays a great role in the lives of a lot of our DMD families.
- 27:26What does that community infrastructure mean for patient outcomes and have you noticed any gaps
- 27:33in ways that we could kind of build that infrastructure a little bit better for patients in their families?
- 27:37Yeah, I think, you know, organizations like Muscular Distribute Association,
- 27:43parent project, Muscular Distribute recently learned about the Jet Foundation, they do
- 27:47find more than just provide educational materials. So they really connect families to resources,
- 27:52support advocacy, they fund research, they fund those studies that they are as exciting
- 27:56that we talked about, but really vital to understanding the impact that we have on patients'
- 28:01quality of life, they facilitate peer relationships, and they help understand, I think, high quality
- 28:07care across treatment centers and advocate for that. So they are a wonderful tool for
- 28:11patients and families. I think one of the biggest remaining gaps is equitable access, right? So
- 28:17that every family has access to specialized clinic, mental health, professional social workers,
- 28:22transition resources, or peer support. So strengthening those community networks is just as
- 28:27important as developing the next therapy. Then there's sort of equitable access when it comes to
- 28:32internet and computers. I think so, Laurence, I think as much as we would like to think that we are
- 28:36all very technological, maybe there's more remote and rural areas where that is not available and
- 28:41they can't jump in on the website, and so then the ownership is on us to be educated and be able to
- 28:46break down really complicated medical terms and explain them to the families in the ways that they
- 28:50understand. One aspect where I think these communities and these resources are incredibly meaningful
- 28:56is in terms of caregiver burden. I think the psycho-social impact of DMD-DP-PAC family dynamics
- 29:02requiring interventions that treat the ecosystem, not just the patients, so I think these
- 29:07organizations do a tremendous job at doing that. And then educating ourselves about what resources
- 29:12we can recommend to families, the camps that we can recommend or talk about, you know,
- 29:16adventures like Tetrisky that we can also add to their life and quality of experiences is something
- 29:22where we have to a little bit more homework and be able to communicate with families about.
- 29:26Have you noticed any disparities in DMD care along racial geographic or socioeconomic lines,
- 29:34either within your practice or in the literature that we should talk about today and see how if
- 29:40there are ways that we could potentially improve that movie before and as well?
- 29:43Yes, I think the literature consistently shows disparities and in diagnosis and again access
- 29:48to specialized care and cortical therapy initiation, clinical trial participation, access to
- 29:53new therapies among racial and ethnic minorities, rural populations and families with fewer
- 29:58financial resources. So many of these disparities are driven by structural barriers, right?
- 30:03So insurance coverage, transportation, language, health literacy, geographic availability of the
- 30:08specialty centers we talked about, rather than differences in the disease itself. So I think it's
- 30:14new therapies emerge, ensuring equitable access is becoming just as important as developing the
- 30:20therapies themselves. Is there anything else in your review of the literature about disparities
- 30:27in DMD care that you learned about that you've probably talked about? Through my review,
- 30:33there are qualitative studies that have shown that parents of children with a child
- 30:37must their district be open experience kind of a cyclical nature of grief and uncertainty,
- 30:42which can affect their ability to process and utilize the health information effectively. So
- 30:47I think they experience chronic stress, severe fatigue and then reduced family function that
- 30:53turns into an emotional urgency of a life-limiting disease that drives a lot of therapeutic misconception
- 30:59and chronic parental burnout, necessitating peer support and targeted psychological therapies,
- 31:04which I think in real life we're still missing that component of supporting the families and the
- 31:08caregivers. Eventually there is for many caregivers breaking point, a caregiver kind of burden spikes
- 31:15exponentially for for non-embellatory patients requiring ventilation forcing caregivers out of
- 31:20the workforce. And so when we see that transition to or the disease progression, there's definitely
- 31:24more struggles that families encounter. And so I think healthier providers should be cognizant of
- 31:29these emotional challenges and provide ongoing support, including psychological therapies for
- 31:35peer support groups to help parents navigate the complexes of DMT care. And I think while we have
- 31:40an incredible support system for the patients and our psychologists that can talk to them,
- 31:44I am struggling to find resources for families where during clinic sessions, for example,
- 31:49we can support them or we can give them a five minute break or we can see in check-in how they're doing.
- 31:54So I think that's another component of DMT care that we need to do a better job of.
- 31:58Yeah, we also did talk a little bit about kinetic geographic disparities and how that affects the
- 32:06way that actually physically being able to see how that kind of affects the way that they're able
- 32:11to actually access care. And I do hope that this is something that's being actively improved as we
- 32:17try to improve our overall attitude to care for our patients.
- 32:21So education will have a big part of that education as a medical student, education as a resident,
- 32:27right? Just so that we know that these are changing populations. And we're essentially, if this is
- 32:32like sci-fi, we're rewriting the trajectory of some of these diseases, but with that comes a lot of
- 32:35responsibility and ownership of how we're doing that. And that education starts really early on.
- 32:41So there's also, you know, so provider variability in when do we start the steroids? Or oh no,
- 32:45it's okay, we can wait and hold off on it, right? So hopefully that is already being addressed through
- 32:50the educational system for us as medical providers. If you could change one thing about how
- 32:57the healthcare system approaches DMD, what would that be? I think if I had to choose one thing,
- 33:03it would be ensuring that every patient has access to comprehensive, multidisciplinary care
- 33:09throughout their entire lifespan. I think medical advances only reach their full potential when
- 33:14they're paired with coordinated cardiology, pulmonella, gene rehabilitation, mental health,
- 33:19social work, transition planning, and adult neuromuscular care. And innovation is incredibly
- 33:24important, but equitable delivery of that innovation is equally important, right? So I think true
- 33:29progress requires integrating scientific innovation with holistic patient-centered support to
- 33:34optimize the quality of extended life. And we have successfully sort of rewritten the biological
- 33:39timeline of Tushen-Moscare Distribute, but we must build the infrastructure to support it.
- 33:44And the future of DMD management demands that we treat the entire lifespan matching our miraculous
- 33:49genetic breakthroughs with equally robust ethical discourse and mental health integration,
- 33:55and seamless adult care transition. So survival shift is the baseline, but now quality of life is
- 34:01the goal, and that's what I want to hope for my patients. Wow, thank you. That was such an amazing
- 34:06conversation. I do have one last question for you. Were listeners who work in healthcare policy,
- 34:14in insurance, or in advocacy, or even, you know, our residents or trainees or medical students?
- 34:19What is the most important thing that they should know and understand about the DMD community
- 34:26right now? Tushen-Moscare Distribute is no longer just a pediatric disease. I think because
- 34:33treatments and supported care have improved, more individuals are living well into adulthood,
- 34:37and they will live on to adulthood, and our healthcare system needs to evolve with them.
- 34:43Policy decisions about insurance coverage, access to specialized centers, transition services,
- 34:49home supports, mental health care, assistive technology, directly influence patients' lives
- 34:53every bit as much as the next scientific breakthrough. So the future of the Shemoscare Distribute
- 34:58isn't defined only by gene therapy. It's defined by whether we can build the healthcare system that
- 35:03allows for every patient to benefit from the extraordinary scientific progress we've already made.
- 35:09And my hope is that we will be able to get closer and closer to the aim and that goal in years to come.
- 35:14Thank you again so much. This is an inspiring and very top provoking conversation.
- 35:21I hope I know I don't know about what this future looks like for my future patients now, right? For
- 35:28patients that I'll be seeing in my general clinic and we'll be working with even maybe even on the
- 35:33inpatient side too down the line, but I truly hope that all of our listeners have also have that bug
- 35:40planted that we're looking in the future about what this means for overall patient care.
- 35:45Absolutely. It was an absolute pleasure and honor to be on your podcast and I hope for
- 35:50a couple of colleagues to get just excited about this. And I think a lot of these lessons,
- 35:54both lights are other patients as well. And I look forward to future collaborations and
- 35:59the evolving life and trajectory of the Shenmueh's Food and History.
- 36:06Thank you for listening to No Brain Behind. No Brain Behind is the official podcast of
- 36:12the Society for Equity and Neuroscience. Opinions shared in this episode are those of the
- 36:16individuals being interviewed. To hear more from sequence, subscribe to the podcast,
- 36:21follow us on social media and give us feedback on what we would like to hear in future episodes.
- 36:25No Brain Behind is brought to you by the Society for Equity and Neuroscience led by Dr. Bruce
- 36:30Obiagli and Lianna Mascro. This podcast is produced by Dr. Vanessa Cooper, Rachel Forman
- 36:36and Parnit Graywall. And our production team includes Sonia Glitur, Tino Delamer said, Joshua
- 36:42Homs, Euchain Hoang and Jake Sossiman. Dr. Angel Kadina Tejada, Gatangeli Doss and Chris Orlando are hosts.
- 36:55[Music]